Myriad: Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer

SALT LAKE CITY, April 07, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics testing and precision medicine, announced today the appointment of Brian Donnelly as chief commercial officer (CCO), effective May 1, 2025.A strategic, results-oriented leader with more than 20 years of experience in healthcare, diagnostics, and medical technology, Donnelly has a proven track record of building and leading high-performing teams, managing multi-billion-dollar P&Ls, and driving growth through innovative go-to-market strategies."Brian brings a unique combination of strategic vision and operational excellence, combined with a passion for patient-centric solutions and a strong focus on commercial execution," said Sam Raha, incoming president and CEO of Myriad Genetics. "He will be a critical member of our leadership team and will play an instrumental role in scaling our business, accelerating product adoption, and driving sustained profitable growth.""I'm thrilled to join Myriad Genetics, which has such a deep commitment to advancing genetic insights and plays a critical ...Full story available on Benzinga.com